SynthesisInternational journal of nanomedicine2025
Actively Targeted Nanoparticles for Enhanced Diagnosis, Treatment, and Vaccination of Tuberculosis: A Systematic Review.
Synthesis in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, hampered by prolonged, toxic treatment regimens that lead to poor patient adherence and drug resistance, as well as diagnostic tools that lack sensitivity and specificity. This systematic review evaluates recent advancement in actively targeted nanoparticle (NP) systems designed to improve TB diagnosis, treatment, and vaccination. Peer-reviewed studies published after 2015 focusing on NPs with active targeting capabilities were analyzed. The findings show that: ligand-functionalized NPs achieve precise, receptor-mediated targeting of infected cells, enhancing therapeutic efficacy; integrating diagnostic elements into these platforms enables rapid, sensitive biomarker detection; and antigen-loaded NPs effectively modulate immune responses, showing significant promise for novel vaccine development. Therefore, actively targeted NPs represent a transformative platform to overcome critical limitations in TB care by offering a unified strategy to improve diagnostic accuracy, therapeutic outcomes, and vaccine-induced immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.